Ionis Pharmaceuticals Inc (IONS) is near the bottom in its industry group according to InvestorsObserver. IONS gets an overall rating of 27. That means it scores higher than 27 percent of stocks. Ionis Pharmaceuticals Inc gets a 13 rank in the Biotechnology industry. Biotechnology is number 99 out of 148 industries.
Click Here to get the full Stock Score Report on Ionis Pharmaceuticals Inc (IONS) Stock.
What do These Ratings Mean?
Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.
These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.
What's Happening With Ionis Pharmaceuticals Inc Stock Today?
Ionis Pharmaceuticals Inc (IONS) stock is lower by -0.38% while the S&P 500 has gained 0.32% as of 1:04 PM on Tuesday, Nov 12. IONS is down -$0.22 from the previous closing price of $56.65 on volume of 260,412 shares. Over the past year the S&P 500 has risen 13.60% while IONS has gained 12.32%. IONS earned $3.08 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 18.32.
